@haleighweaver5's compounded GLP-1 claims need context

What did @haleighweaver5 actually say?

She told her 26,000+ viewers to DM her on Instagram to get a link for "affordable turseptide and semaglutide" for weight loss. That's the whole pitch. No clinical context, no mention of a prescriber, no safety information. Just: slide into my DMs and I'll hook you up.

To be fair, she didn't make outlandish efficacy claims. She didn't promise you'd lose 40 pounds or reverse your diabetes. The problem isn't what she said about the drugs. It's the distribution method she's describing, which raises serious regulatory and safety red flags that her viewers deserve to understand before they send that DM.

Also worth noting: she repeatedly mispronounces tirzepatide as "turseptide," which isn't a real medication. That's a small thing, but it does raise questions about how deeply she understands what she's promoting.

Does the science back this up?

The drugs themselves, semaglutide and tirzepatide, are well-supported by clinical evidence. The issue here isn't the science behind GLP-1 receptor agonists. It's the unregulated referral chain she's describing.

Semaglutide (the active ingredient in Ozempic and Wegovy) has robust trial support. The STEP 1 trial (Wilding et al., 2021, NEJM) showed a mean body weight reduction of 14.9% over 68 weeks in adults with obesity. Tirzepatide's SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed even stronger results, up to 20.9% weight reduction at the highest dose. These are real, meaningful outcomes in controlled clinical settings with medical supervision.

Compounded versions of these drugs exist in a different regulatory space. The FDA does not evaluate compounded drugs for safety, efficacy, or quality before they reach patients. That doesn't make them automatically dangerous, but it does mean the burden of vetting falls entirely on the patient, and most patients don't have the tools to do that vetting.

What did they get wrong (or right)?

What she got right: compounded GLP-1 medications can be significantly cheaper than brand-name versions, and cost is a legitimate barrier to access. That's not spin. Wegovy's list price exceeds $1,300 per month without insurance, and for many patients compounding is the only financially realistic option.

What she got wrong, or at least dangerously incomplete: directing people to DM her for a link bypasses every safeguard that exists in regulated telehealth. There is no indication that a licensed prescriber is involved, that the compounding pharmacy is 503A or 503B accredited, or that patients are being screened for contraindications like a personal or family history of medullary thyroid carcinoma, pancreatitis, or severe GI conditions.

Referral arrangements where influencers collect commissions for directing patients to compounding pharmacies or telehealth providers can also violate federal anti-kickback statutes, depending on structure. The FTC has been increasingly active on undisclosed affiliate relationships in health promotion. None of this is disclosed in her video.

What should you actually know?

If you're considering compounded semaglutide or tirzepatide, the access pathway matters as much as the drug itself. A legitimate route involves a licensed clinician reviewing your medical history, a prescription issued through proper channels, and a pharmacy that operates under state board oversight and follows USP standards.

The FDA issued warnings in 2023 and 2024 about compounded semaglutide products, specifically flagging risks associated with dosing errors when patients self-administer from multi-dose vials without clinical guidance. Getting a link from an influencer's Instagram DM does not come with dosing guidance, clinical oversight, or any accountability if something goes wrong.

Cost should not be a barrier to safe access, and regulated telehealth platforms do offer compounded GLP-1 options at lower price points than brand-name drugs, with actual prescribers involved. That's the version of "affordable" that doesn't put you at risk.

Our bottom line

The drugs she's promoting have legitimate, well-documented clinical use for weight management. The way she's promoting them does not meet any reasonable standard for safe patient access. "DM me on Instagram" is not a healthcare referral system. It's an influencer funnel, and your health shouldn't move through one.

If you're exploring GLP-1 therapy, work with a licensed provider who can review your full health picture, explain the actual risks, and monitor your progress. That process exists for reasons that a viral TikTok cannot replace.